Caribou Biosciences Inc
CRBU1.570USD
+0.090+6.08%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
146.74MMarket Cap
LossP/E TTM
More Details of Caribou Biosciences Inc Company
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
Caribou Biosciences Inc Info
Ticker SymbolCRBU
Company nameCaribou Biosciences Inc
IPO dateJul 23, 2021
CEOHaurwitz (Rachel E)
Number of employees147
Security typeOrdinary Share
Fiscal year-endJul 23
Address2929 7Th Street, Ste 120
CityBERKELEY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94710
Phone15109826030
Websitehttps://www.cariboubio.com/
Ticker SymbolCRBU
IPO dateJul 23, 2021
CEOHaurwitz (Rachel E)
Company Executives of Caribou Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-29250.00%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
+17360.00%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Ms. Ruhi A. Khan
Ms. Ruhi A. Khan
Chief Business Officer
Chief Business Officer
--
--
Dr. Scott N. Braunstein, M.D.
Dr. Scott N. Braunstein, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew L. Guggenhime
Mr. Andrew L. Guggenhime
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Natalie R. Sacks, M.D.
Dr. Natalie R. Sacks, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Barbara G. McClung, J.D.
Ms. Barbara G. McClung, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
381.25K
-29250.00%
Mr. Sriram (Sri) Ryali
Mr. Sriram (Sri) Ryali
Chief Financial Officer
Chief Financial Officer
17.36K
+17360.00%
Dr. Rachel E. Haurwitz, Ph.D.
Dr. Rachel E. Haurwitz, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Ms. Ran Zheng
Ms. Ran Zheng
Independent Director
Independent Director
--
--
Dr. Dara Richardson-Heron, M.D.
Dr. Dara Richardson-Heron, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
1.82M
82.85%
Rest of world
377.00K
17.15%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Jan 31
Updated: Sat, Jan 31
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pfizer Inc
5.02%
The Vanguard Group, Inc.
4.61%
Haurwitz (Rachel E. Ph.D.)
3.68%
Millennium Management LLC
3.44%
Kynam Capital Management LP
3.28%
Other
79.97%
Shareholders
Shareholders
Proportion
Pfizer Inc
5.02%
The Vanguard Group, Inc.
4.61%
Haurwitz (Rachel E. Ph.D.)
3.68%
Millennium Management LLC
3.44%
Kynam Capital Management LP
3.28%
Other
79.97%
Shareholder Types
Shareholders
Proportion
Investment Advisor
17.01%
Hedge Fund
13.83%
Investment Advisor/Hedge Fund
5.57%
Corporation
5.02%
Individual Investor
4.72%
Research Firm
2.40%
Private Equity
0.83%
Venture Capital
0.47%
Bank and Trust
0.09%
Other
50.07%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
336
36.52M
71.18%
+8.50K
2025Q3
343
36.51M
75.34%
-3.42M
2025Q2
344
39.93M
84.21%
-9.67M
2025Q1
343
49.60M
89.75%
-33.86M
2024Q4
341
57.02M
91.20%
-746.04K
2024Q3
336
56.25M
89.23%
-1.72M
2024Q2
332
57.28M
88.69%
-12.92M
2024Q1
319
69.74M
90.55%
-12.04M
2023Q4
311
71.96M
89.62%
-1.70M
2023Q3
307
73.59M
61.71%
+24.32M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pfizer Inc
4.69M
5.02%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
4.23M
4.52%
+137.06K
+3.35%
Sep 30, 2025
Haurwitz (Rachel E. Ph.D.)
3.44M
3.68%
-87.08K
-2.47%
Apr 22, 2025
Millennium Management LLC
3.22M
3.44%
+1.67M
+107.44%
Sep 30, 2025
Kynam Capital Management LP
3.07M
3.28%
--
--
Sep 30, 2025
Two Sigma Investments, LP
2.01M
2.15%
-365.33K
-15.37%
Sep 30, 2025
ACATIS Investment Kapitalverwaltungsgesellschaft GmbH
2.00M
2.14%
--
--
Sep 30, 2025
SELECTRA Management Company S.A.
1.65M
1.77%
+120.00K
+7.84%
Nov 30, 2025
BlackRock Institutional Trust Company, N.A.
1.45M
1.55%
-380.57K
-20.78%
Sep 30, 2025
abrdn Inc.
1.39M
1.49%
+491.33K
+54.74%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AXS Green Alpha ETF
1.24%
WisdomTree BioRevolution Fund
0.52%
Avantis US Small Cap Equity ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
DFA Dimensional US Core Equity Market ETF
0%
Global X Genomics & Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ProShares Hedge Replication ETF
0%
Pacer WealthShield ETF
0%
ProShares UltraPro Russell2000
0%
View more
AXS Green Alpha ETF
Proportion1.24%
WisdomTree BioRevolution Fund
Proportion0.52%
Avantis US Small Cap Equity ETF
Proportion0.01%
Schwab U.S. Small-Cap ETF
Proportion0.01%
DFA Dimensional US Core Equity Market ETF
Proportion0%
Global X Genomics & Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Pacer WealthShield ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
